CTOs on the Move

Lutonix

www.lutonix.com

 
Lutonix is a Maple Grove, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.lutonix.com
  • 7351 Kirkwood Ln N Ste 138
    Maple Grove, MN USA 55369
  • Phone: 763.445.2352

Executives

Name Title Contact Details

Similar Companies

Amunix

Amunix is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ynsect

Ÿnsect is the world leader in the production of protein and natural insect fertilizers. Founded in 2011 in Paris, France, by both scientists and environmental activists, Next40 and B Corp-certified, the company processes insects into high-end, high-value ingredients for pets, fish, plants and humans. From its purpose-built state-of-the-art farms, Ÿnsect offers a long-term, sustainable, organic solution to accelerate protein and plant consumption. Ÿnsect uses pioneering proprietary technology covered by 377 patents across 44 categories, to produce lesser and yellow mealworms in fully automated vertical farms. Ÿnsect runs three production sites, one in Dole, France (commissioned 2016), one in the Netherlands (2017), one in the USA (since 2022), and a third site, the world`s largest vertical farm, in Amiens in France, is currently under construction. The company, which employs 360+ people, has raised around $ 500 million from major global investment funds, banks and public bodies and exports its products around the world.

Tomtec Inc

Tomtec Inc is a Hamden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taueret Laboratories

Taueret Laboratories is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corvidia

Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company`s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia`s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.